A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma

Time Perspective: this study does have a retrospective component involving a subset of
patients.

For more information regarding BMS clinical trial participation, please visit
www.BMSStudyConnect.com.

Inclusion Criteria:

- Diagnosis of unresectable or metastatic melanoma

- Age of 18 years or older at time of entry into the study

- Patients who have initiated treatment for unresectable or metastatic melanoma at
medical practice (e.g. community-based, office-based, hospital-based, academic
setting)within 21 days before informed consent for this study OR in the case where
treatment has not yet been initiated, documentation that the treatment strategy was
determined before informed consent for this study, and treatment must be initiated
within 28 days after informed consent

- Ipilimumab-treated patients must be receiving treatment for the indication(s) approved
in their country of residence or where they are receiving treatment

Exclusion Criteria:

- Current or pending participation in a clinical trial examining therapy for the
treatment of any cancer (including unresectable or metastatic melanoma)

- Current use of therapy to treat a primary cancer other than melanoma